Clinical Trial: NCT06478043
A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Zhejiang Cancer Hospital |
| Information Provided By: | Zhejiang Cancer Hospital |
| Last Update Posted: | 2026-08-27 |
Study Overview
Brief Summary
This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of ivonescimab combined with irinotecan liposome for relapsed small cell lung cancer, who progressed on PD-(L)1 -based first-line therapy.
Official Title
Phase II Study of AK112 Combined With Irinotecan Liposome in Patients With SCLC Who Progressed on Immune Checkpoint Inhibitors and Chemotherapy.
Conditions
Small-cell Lung Cancer
Intervention / Treatment
- Drug: ivonescimab
- Drug: irinotecan liposome
Other Study ID Numbers
- IRB-2024-543 (IIT)
Start Date (Actual)
2024-10-16
Primary Completion Date (Actual)
2026-06-30
Study Completion Date (Actual)
2026-06-30
Enrollment (Actual)
60
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Zhejiang Cancer Hospital |
| Information Provided By: | Zhejiang Cancer Hospital |
| Last Update Posted: | 2026-08-27 |
Study Overview
Brief Summary
This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of ivonescimab combined with irinotecan liposome for relapsed small cell lung cancer, who progressed on PD-(L)1 -based first-line therapy.
Official Title
Phase II Study of AK112 Combined With Irinotecan Liposome in Patients With SCLC Who Progressed on Immune Checkpoint Inhibitors and Chemotherapy.
Conditions
Small-cell Lung Cancer
Intervention / Treatment
- Drug: ivonescimab
- Drug: irinotecan liposome
Other Study ID Numbers
- IRB-2024-543 (IIT)
Start Date (Actual)
2024-10-16
Primary Completion Date (Actual)
2026-06-30
Study Completion Date (Actual)
2026-06-30
Enrollment (Actual)
60
Study Type
Interventional
Phase
Phase 2